← Back to Search

Dietary Supplement

Antioxidant Supplements for Long COVID-19

Phase < 1
Waitlist Available
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with positive COVID testing (AB, RT PCR) and mild-severe symptoms based on COVID symptom list
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy
Awards & highlights

Summary

This trial is testing if a mix of supplements can help people with long-term COVID-19 symptoms. The supplements may reduce body damage and inflammation to improve these lingering symptoms.

Who is the study for?
This trial is for individuals who have tested positive for COVID-19 and are experiencing mild to severe long-haul symptoms. They must not have allergies or adverse reactions to NAC, ALA, or GSH, no meat product/gelatin allergies (alpha gal allergy), and no history of severe sulfa sensitivity.
What is being tested?
The study tests if glutathione combined with NAC and ALA can improve long COVID symptoms. Participants will be randomly assigned to receive these supplements with or without a multivitamin and magnesium, while their health status is monitored through questions and blood samples.
What are the potential side effects?
Potential side effects may include allergic reactions in those sensitive to the ingredients used: NAC, ALA, liposomal GSH. Side effects could range from mild digestive discomfort to more serious allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I tested positive for COVID and have symptoms ranging from mild to severe.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~symptoms will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy
This trial's timeline: 3 weeks for screening, Varies for treatment, and symptoms will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assess Changes in Symptoms of Post-Acute Sequelae of COVID (PASC)
COVID Severity of Symptoms Questionnaire
Change in Quality of Life Using SF-36 Survey
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm AExperimental Treatment1 Intervention
Subjects randomized into Group A will take the following amount for 28 days * 4 capsules of NAC (600mg each) once in the morning and once in the evening * 1 tablet (600mg) of Alamax CR once in the morning and once in the evening * 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening
Group II: Arm BActive Control1 Intervention
Subjects randomized into Group B will be taking a multivitamin and magnesium for 14 days. Afterwards, they will take the following for 14 days. * 4 capsules of NAC (600mg each) once in the morning and once in the evening * 1 tablet (600mg) of Alamax CR once in the morning and once in the evening * 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Coronavirus, such as NAC, Alamax CR, and liposomal GSH, focus on reducing oxidative stress and enhancing cellular detoxification and immune function. NAC helps to liquefy mucus and combat oxidative stress, while glutathione (GSH) acts as a critical antioxidant protecting cells from damage and supporting immune function. Alpha lipoic acid (ALA) further contributes by regenerating other antioxidants like GSH. These mechanisms are vital for managing the inflammatory and oxidative damage seen in COVID-19 patients, potentially improving outcomes by reducing cellular damage and supporting overall immune health.
Exploring the Pharmacological Mechanism of the Effective Chinese Medicines Against Gynecological Cancer Based on Meta-Analysis Combined With Network Pharmacology Analysis.Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19.Chemical composition and pharmacological mechanism of shenfu decoction in the treatment of novel coronavirus <i>pneumonia</i> (COVID-19).

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor
559 Previous Clinical Trials
1,929,958 Total Patients Enrolled
Hudson Valley Healing Arts CenterUNKNOWN

Media Library

Alpha lipoic acid (ALA) (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05371288 — Phase < 1
Coronavirus Research Study Groups: Arm B, Arm A
Coronavirus Clinical Trial 2023: Alpha lipoic acid (ALA) Highlights & Side Effects. Trial Name: NCT05371288 — Phase < 1
Alpha lipoic acid (ALA) (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05371288 — Phase < 1
Coronavirus Patient Testimony for trial: Trial Name: NCT05371288 — Phase < 1
~33 spots leftby Sep 2025